Outcome of myeloma patients with COVID5 19 on active lenalidomide-based therapy: 6 Does lenalidomide protect from severe 7 COVID-19?
Tailor, Imran K.
Alshehry, Nawal F.
Zaidi, Syed Z.
Marei, Mohammed A.
Motabi, Ibrahim H.
Altaf, Syed Y.
MetadataMostrar registro completo
Patients with haematological cancers and concurrent coronavirus disease 2019 (COVID-19) reportedly have poor outcomes as indicated by high hospitalisation rates, high case fatality rates in mechanically ventilated patients, and a high mortality rate of ≥10% , , . A recent small study reported a high mortality rate among patients with myeloma and concurrent COVID-19 infection . Interestingly, one large study reported that active or recent chemotherapy was not a predictor of severe disease, whereas checkpoint inhibitor therapy and age over 65 years were associated with adverse outcomes . Here we describe the outcomes of three consecutive patients with myeloma and concurrent COVID-19 infection admitted at our tertiary care centre between April and June 2020, whilst on lenalidomide-based therapy, two of whom underwent autologous stem cell transplant, with at least 30 days of follow-up.
Link para o recursohttps://doi.org/10.1016/j.hemonc.2020.08.002
Estadísticas Google Analytics
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.